A fresh study by Transparency Market Research (TMR) notifies that the global soft tissue allografts market was dominated by Allergan, plc. in 2016, and the company is poised to sustain its strong market position in the near future via its impressive product portfolio, geographical presence, and frequent strategic acquisitions. For example, Allergan completed the acquisition of Acelity L.P. Inc.’s LifeCell Corporation for US$2.9 bn in February 2017. This move will help the company to make a foray into regenerative medicine and add to its high-quality and durable portfolio. Besides the commercial products of LifeCell, Allergan will also acquire the New Jersey Company’s innovative manufacturing capabilities and its research and development operations.
The TMR report also identifies some of the other prominent companies currently operating in The Global Soft Tissue Allografts Market, namely Zimmer Biomet, Lattice Biologics Ltd., AlonSource Group, AlloSource, MiMedix Group, Inc., CONMED Corporation, Organogenesis Inc., RTI Surgical, Inc., Integra LifeSciences Corporation, Globus Medical Inc, Straumann Holding AG, Osiris Therapeutics, Inc., Arthrex, Inc., Xtant Medical, Alliqua BioMedical, Inc, C. R. Bard, Inc (Davol Inc.), B. Braun Melsungen AG, and Bone Bank Allograft.
As per the projections of the TMR report, the demand in the global soft tissue allografts market will swell at a healthy CAGR of 6.3% during the forecast period of 2017 to 2025. The report estimates the market for soft tissue allografts, across the world, to be worth US$6.2 bn by the end of 2025, substantially up from its evaluated valuation of US$3.6 bn in 2016. Based on product type, collagen allograft was the most profitable segment, owing to its applications in aesthetics surgery, wound care, and orthopedic surgeries. Application-wise, wound care category held major market share in 2016, followed by dentistry. Geographically, North America currently serves the maximum demand in the global soft tissue allografts market.
High Cost Remains Primary Restraint
While high cost of procedures continues to challenge the market for soft tissue allografts, especially in the emerging economies, the lack of defined reimbursement policies is also obstructing the market expansion. In addition to that, complications pertaining to increased risk of infection and immune response such as disruption of infected anastomotic rigid line with a rupture, microbial infection, and bowel formation is hindering the proper prosperity of the global soft tissue allografts market.
Request to View Brochure of Report -
Geriatrics and Athletes Driving Demand
For well over a century, soft tissue allografts have been considered a successful procedure, and each year, nearly 1 million allografts are transplanted in the U.S. alone. Soft tissue allografts are substitute tissues that are used to reconstruct deficient ligaments, spinal surgery, torn menisci, and osteochondral defects during knee surgery. Soft tissue allografts undergo a three-stage safety screening process of donor screening, laboratory testing, and tissue preparation. Soft tissue allografts can be made up of bone, tendons, cartilage, skin, heart valves, and veins used for transplant in different types of surgeries.
In the recent past, the usage of soft tissue allografts has grown due to increase in the number of cases in dental implants and orthopedic surgery. Escalating geriatric population, growing demand for new technological advancement for production of new tissues by tissue banks, and rise in demand of soft tissue allografts among athletes of numerous sports and other walks of life are some of the key factors driving the demand in the global soft tissue allografts market. Increase in ACL surgery, escalating incidences of diabetes foot ulcer, growing popularity of cosmetic surgery to treat facial disorders with new technologies are some of the other factors favoring the global soft tissue allografts market.
Comments
Post a Comment